#United States #Chou2 Pharma #Ethos Discovery #Canine Epilepsy #Narberth

Chou2 Pharma Announces Partnership with Ethos Discovery for Canine Epilepsy Research

Chou2 Pharma LLC, known for its commitment to advancing cannabinoid therapies in veterinary medicine, is excited to announce its collaboration with Ethos Discovery. This partnership will focus on studying a novel animal drug formulation aimed at treating idiopathic epilepsy in dogs. Scheduled to commence in early 2025, the initial study will evaluate the pharmacokinetics of this potential treatment, followed by a proof-of-concept efficacy trial for canines suffering from epilepsy.

Brian Segebrecht, CEO of Chou2 Pharma, expressed enthusiasm about working alongside Dr. Khanna and his team from Ethos Discovery, emphasizing the importance of collaboration in bringing innovative therapeutic options to pets with unmet medical needs.

John Payne, Co-founder and Executive Chairman of Chou2 Pharma, highlighted the company's foundational vision, which is to utilize its precise cannabinoid formulating platform to elevate veterinary practices through groundbreaking pharmaceuticals. He remarked, "It's rewarding to see our vision coming to life in such an important therapeutic area," underscoring the significance of further cooperation with Ethos Discovery.

Idiopathic epilepsy poses considerable health challenges for dogs, with a significant percentage—ranging from 30% to 40%—being resistant to existing treatments. These dogs often continue to experience repeated and severe seizures even while on medication. Available anti-epileptic drugs are frequently administered in combination, which can lead to a concerning balance between managing the condition and minimizing side effects. Some of these side effects may significantly deteriorate the overall quality of life for affected canines.

Dr. Khanna, representing Ethos Discovery, noted, "This therapeutic area in veterinary medicine could benefit immensely from a more consistently effective drug that boasts a better safety profile." He expressed optimism that through preliminary work with Chou2 Pharma's novel drug for idiopathic epilepsy, they can strive to enhance both the quality and safety of treatment options in veterinary care.

Investment and Future Aspirations

Chou2 Pharma is also actively seeking additional funding through an ongoing Series A round of equity financing. They are open to discussions with potential strategic partners to support their mission. To facilitate this fundraising initiative, Chou2 Pharma has engaged a FINRA-registered broker-dealer specialized in the animal pharmaceutical sector, aiming to identify opportunities for co-development and future commercial partnerships.

About Ethos Discovery

Ethos Discovery operates as a nonprofit organization dedicated to innovating medical treatments and assessments that benefit both pets and humans. The organization emphasizes targeted research and clinical trials to confront medical challenges prevalent in veterinary medicine, further enhancing health outcomes for animals and their caregivers. Supported by Ethos Veterinary Health, the organization is uniquely positioned to collaborate with clinical hospitals and leading experts to promote impactful research in veterinary care.

For more detailed information or to explore potential partnerships, you may visit www.ethosdiscovery.org.

In summary, Chou2 Pharma's partnership with Ethos Discovery presents a promising leap forward in addressing canine idiopathic epilepsy, showcasing the immense potential of cannabinoid-based therapies in veterinary medicine. As the study progresses, it will undoubtedly raise hopes among pet owners seeking effective management strategies for their canine companions battling this challenging condition.